Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): Case report

In Keun Choi, Byung Soo Kim, Kyung A. Lee, Sookwon Ryu, Hee Yun Seo, Hyeryoung Sul, Jong Gwon Choi, Hwa Jung Sung, Kyong Hwa Park, So Young Yoon, Sang Cheul Oh, Jae Hong Seo, Chul Won Choi, Sang Won Shin, Soo-Young Yoon, Yunjung Cho, Young Kee Kim, Yeul Hong Kim, Jun Suk Kim

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Chronic neutrophilic leukemia (CNL) is a rare hematologic disorder, for which there is no standard therapy. Recently, STI (imatinib mesylate) has been shown to be effective in treating patients with chronic myeloproliferative disorder (CMPD) displaying the translocation of the PDGFβR gene. Here, we present a case of a patient with CNL carrying t(15;19)(q13;p13.3) who achieved a cytogenetic remission following treatment with imatinib, 400 mg daily. After failure of alpha interferon and hydroxyurea therapy, a durable and complete clinical and cytogenic remission was induced by imatinib. To our knowledge, this is the first case with CNL who showed complete response with cytogenic remission after treatment of imatinib. The mechanism of response to this molecule is unknown in our case (other oncogenes than c-kit, tyrosine kinase, or PDGFR may be involved). The patient remains in complete remission with an excellent performance status after 7 months of therapy. We demonstrate here that imatinib can induce a clinical and cytogenetic response in a case of CNL associated with a novel translocation other than a 5q33 rearrangement. Further studies including the molecular cloning of the t(15;19)(q13;p13.3) will be important in understanding the pathophysiology of CNL with a heterogeneous clinical course and the exploitation of the basic mechanisms of imatinib treatment.

Original languageEnglish
Pages (from-to)366-369
Number of pages4
JournalAmerican Journal of Hematology
Volume77
Issue number4
DOIs
Publication statusPublished - 2004 Dec 1

Fingerprint

Leukemia, Neutrophilic, Chronic
Cytogenetics
Therapeutics
Myeloproliferative Disorders
Hydroxyurea
Molecular Cloning
Sexually Transmitted Diseases
Oncogenes
Interferon-alpha
Protein-Tyrosine Kinases
Imatinib Mesylate

Keywords

  • Chronic neutrophilic leukemia
  • Imatinib mesylate
  • t(15;19)

ASJC Scopus subject areas

  • Hematology

Cite this

Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19) : Case report. / Choi, In Keun; Kim, Byung Soo; Lee, Kyung A.; Ryu, Sookwon; Seo, Hee Yun; Sul, Hyeryoung; Choi, Jong Gwon; Sung, Hwa Jung; Park, Kyong Hwa; Yoon, So Young; Oh, Sang Cheul; Seo, Jae Hong; Choi, Chul Won; Shin, Sang Won; Yoon, Soo-Young; Cho, Yunjung; Kim, Young Kee; Kim, Yeul Hong; Kim, Jun Suk.

In: American Journal of Hematology, Vol. 77, No. 4, 01.12.2004, p. 366-369.

Research output: Contribution to journalArticle

@article{ef7fa5b0001146718534b3024f3a79d9,
title = "Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): Case report",
abstract = "Chronic neutrophilic leukemia (CNL) is a rare hematologic disorder, for which there is no standard therapy. Recently, STI (imatinib mesylate) has been shown to be effective in treating patients with chronic myeloproliferative disorder (CMPD) displaying the translocation of the PDGFβR gene. Here, we present a case of a patient with CNL carrying t(15;19)(q13;p13.3) who achieved a cytogenetic remission following treatment with imatinib, 400 mg daily. After failure of alpha interferon and hydroxyurea therapy, a durable and complete clinical and cytogenic remission was induced by imatinib. To our knowledge, this is the first case with CNL who showed complete response with cytogenic remission after treatment of imatinib. The mechanism of response to this molecule is unknown in our case (other oncogenes than c-kit, tyrosine kinase, or PDGFR may be involved). The patient remains in complete remission with an excellent performance status after 7 months of therapy. We demonstrate here that imatinib can induce a clinical and cytogenetic response in a case of CNL associated with a novel translocation other than a 5q33 rearrangement. Further studies including the molecular cloning of the t(15;19)(q13;p13.3) will be important in understanding the pathophysiology of CNL with a heterogeneous clinical course and the exploitation of the basic mechanisms of imatinib treatment.",
keywords = "Chronic neutrophilic leukemia, Imatinib mesylate, t(15;19)",
author = "Choi, {In Keun} and Kim, {Byung Soo} and Lee, {Kyung A.} and Sookwon Ryu and Seo, {Hee Yun} and Hyeryoung Sul and Choi, {Jong Gwon} and Sung, {Hwa Jung} and Park, {Kyong Hwa} and Yoon, {So Young} and Oh, {Sang Cheul} and Seo, {Jae Hong} and Choi, {Chul Won} and Shin, {Sang Won} and Soo-Young Yoon and Yunjung Cho and Kim, {Young Kee} and Kim, {Yeul Hong} and Kim, {Jun Suk}",
year = "2004",
month = "12",
day = "1",
doi = "10.1002/ajh.20197",
language = "English",
volume = "77",
pages = "366--369",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19)

T2 - Case report

AU - Choi, In Keun

AU - Kim, Byung Soo

AU - Lee, Kyung A.

AU - Ryu, Sookwon

AU - Seo, Hee Yun

AU - Sul, Hyeryoung

AU - Choi, Jong Gwon

AU - Sung, Hwa Jung

AU - Park, Kyong Hwa

AU - Yoon, So Young

AU - Oh, Sang Cheul

AU - Seo, Jae Hong

AU - Choi, Chul Won

AU - Shin, Sang Won

AU - Yoon, Soo-Young

AU - Cho, Yunjung

AU - Kim, Young Kee

AU - Kim, Yeul Hong

AU - Kim, Jun Suk

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Chronic neutrophilic leukemia (CNL) is a rare hematologic disorder, for which there is no standard therapy. Recently, STI (imatinib mesylate) has been shown to be effective in treating patients with chronic myeloproliferative disorder (CMPD) displaying the translocation of the PDGFβR gene. Here, we present a case of a patient with CNL carrying t(15;19)(q13;p13.3) who achieved a cytogenetic remission following treatment with imatinib, 400 mg daily. After failure of alpha interferon and hydroxyurea therapy, a durable and complete clinical and cytogenic remission was induced by imatinib. To our knowledge, this is the first case with CNL who showed complete response with cytogenic remission after treatment of imatinib. The mechanism of response to this molecule is unknown in our case (other oncogenes than c-kit, tyrosine kinase, or PDGFR may be involved). The patient remains in complete remission with an excellent performance status after 7 months of therapy. We demonstrate here that imatinib can induce a clinical and cytogenetic response in a case of CNL associated with a novel translocation other than a 5q33 rearrangement. Further studies including the molecular cloning of the t(15;19)(q13;p13.3) will be important in understanding the pathophysiology of CNL with a heterogeneous clinical course and the exploitation of the basic mechanisms of imatinib treatment.

AB - Chronic neutrophilic leukemia (CNL) is a rare hematologic disorder, for which there is no standard therapy. Recently, STI (imatinib mesylate) has been shown to be effective in treating patients with chronic myeloproliferative disorder (CMPD) displaying the translocation of the PDGFβR gene. Here, we present a case of a patient with CNL carrying t(15;19)(q13;p13.3) who achieved a cytogenetic remission following treatment with imatinib, 400 mg daily. After failure of alpha interferon and hydroxyurea therapy, a durable and complete clinical and cytogenic remission was induced by imatinib. To our knowledge, this is the first case with CNL who showed complete response with cytogenic remission after treatment of imatinib. The mechanism of response to this molecule is unknown in our case (other oncogenes than c-kit, tyrosine kinase, or PDGFR may be involved). The patient remains in complete remission with an excellent performance status after 7 months of therapy. We demonstrate here that imatinib can induce a clinical and cytogenetic response in a case of CNL associated with a novel translocation other than a 5q33 rearrangement. Further studies including the molecular cloning of the t(15;19)(q13;p13.3) will be important in understanding the pathophysiology of CNL with a heterogeneous clinical course and the exploitation of the basic mechanisms of imatinib treatment.

KW - Chronic neutrophilic leukemia

KW - Imatinib mesylate

KW - t(15;19)

UR - http://www.scopus.com/inward/record.url?scp=9644272765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9644272765&partnerID=8YFLogxK

U2 - 10.1002/ajh.20197

DO - 10.1002/ajh.20197

M3 - Article

C2 - 15551277

AN - SCOPUS:9644272765

VL - 77

SP - 366

EP - 369

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 4

ER -